EB140 heats up during discussions of proposed changes to resolution on TOR of Overall Programme Review of GSPOA
* (The author thanks the PHM Watchers for their notes of the WHO EB140 deliberations).
Feb 24, 2017 – U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents
Full Video of Event: https://www.youtube.com/watch?v=-stSKXmY-Wc
On Friday, February 24, 2017, KEI hosted a meeting exploring compulsory licensing in the United States.
Title: History, Experiences, and Prospects of Compulsory Licensing on Medical Patents in the United States
Date: Friday February 24, 2017
Location: Kaiser Permanente Center for Total Health
700 Second St. NE (near Union Station)
Washington, DC 20002
Chilean Cámara de Diputados votes overwhelmingly to advance compulsory licensing of drug patents.
The Cámara de Diputados of the Chilean Congress voted on January 25, 2017 in favor of Resolution 798, calling on the government to implement compulsory licenses on drugs for cancer and other diseases. The vote was 67 yes, 0 no, and 32 abstentions. The resolution was put forward by Giorgio Jackson and six other members (V. Mirosevic, Miguel Alvarado, Karla Rubilar, Juan Luis Castro, Gabriel Boric, and Victor Torres). Continue Reading
EB140: Statement of India on the Report of the United Nations High-Level Panel on Access to Medicines
On the morning of Monday, 23 January 2017, India delivered the following intervention at the 140th session of the World Health Organization’s Executive Board requesting the “explicit inclusion” of the United Nations Secretary-General’s High-Level Panel Report in the “provisional agenda of the EB140 as a separate agenda item under item 8.”
In making the case for the inclusion of the UN HLP in the WHO’s Executive Board deliberations, India articulate the following:
Spinraza: KEI asks DHHS Office of the Inspector General (OIG) to investigate a failure to disclose federal funding in patents
KEI has asked the DHHS Office of Inspector General (OIG) to investigate a failure to disclose federal funding of patents on nusinersen, a drug developed by Ionis Pharmaceuticals (formerly known as Isis Pharmacetuicals) with BioGen, and sold under the trade name Spinraza.
A copy of the 22 page letter to OIG is available here.
Klobuchar Drug Importation Amendment Sees Votes Crossing the Aisle
At 11:06 P.M. on January 11, 2017, during the so-called “Vote-A-Rama”, the Senate considered an amendment put forward by Sen. Amy Klobuchar, D-Minn., and co-sponsored by Sen. Bernie Sanders, I-Vt., on the parallel importation of prescription drugs from Canada. Continue Reading
Groups Object to Army Proposal to Give Sanofi a Monopoly on Patents for Taxpayer-Funded Zika Vaccine
KNOWLEDGE ECOLOGY INTERNATIONAL
FOR IMMEDIATE RELEASE
12 JANUARY 2017
CONTACT: Zack Struver, zack.struver@keionline.org, +1 (202) 332-2670
Groups Object to Army Proposal to Give Sanofi a Monopoly on Patents for Taxpayer-Funded Zika Vaccine
KEI initial opposition to U.S. Army grant of exclusive license to Sanofi on patents for Zika virus vaccine
December 21, 2016 — KEI has filed comments with the U.S. Army Medical Research and Materiel Command (USAMRMC) on the proposed grant of an exclusive license to Sanofi on patents on a vaccine for Zika Virus.
Colombia finalizes 44% price reduction of leukemia drug Glivec
The Colombian Ministry of Health has finalized the price reduction of Glivec, Novartis’s +$47 billion leukemia drug, with a decrease in price from 368 pesos per milligram to 206.42 pesos per mg.
SCP25: Closing Statement of the Republic of South Africa
On Thursday, 15 December 2016, South Africa delivered this poignant, closing statement at WIPO’s Standing Committee on the Law of Patents (SCP). Negotiations broke down on the issue of future work, as the European Union and Group B refused to permit discussions of the Report of the UN Secretary-General’s High-Level Panel on Access to Medicines at future sessions of the SCP.
According to the WIPO website,